Revolutionizing the Treatment of Autoimmune Diseases
Addressing significant unmet needs in the field of autoimmunity through the development of novel patented therapies for treatment of disease.
AnTolRx’s vision is to build a platform that selectively targets pathogenic immune cells providing a unique tolerogenic signal to induce an anti-inflammatory phenotype and better treat diseases.
We are excited to announce that we will be presenting at the 3rd Antigen-Specific Immune Tolerance Drug Development conference. We will be discussing AnTolRx's antigen-specific nanoformulation platform for the treatment of autoimmune diseases! Come join us in Boston...
We are excited to attend the 38th annual J.P. Morgan Healthcare Conference in San Francisco, CA on January 13th through the 16th.